Patient-Level Treatment Drivers — Route of Administration, Psoriatic Arthritis, and Comorbidity Considerations

Strober examines how patient preference for oral versus injectable therapy and the presence and pattern of psoriatic arthritis.

Effective psoriasis management increasingly depends on a treatment selection framework that extends beyond skin severity scores to encompass the full clinical and contextual profile of the individual patient. Route of administration is among the most practically influential of these factors. Many patients express an instinctive preference for oral medications, but that preference is rarely absolute and often shifts when the clinical conversation addresses the full picture of treatment burden — including how often injections actually occur at maintenance and how that compares with the commitment of daily oral dosing. For patients who prioritize the fewest possible interactions with a therapy once disease is controlled, the every-12-weeks maintenance schedule of an IL-23 biologic may ultimately be more acceptable than a once-daily oral pill. The clinician's role is to surface these preferences explicitly rather than assume them, and to provide the comparative context patients need to make an informed choice.

Psoriatic arthritis (PsA) — its presence, severity, and anatomical pattern — is among the most consequential determinants of mechanism selection in patients with psoriatic disease. IL-17 inhibitors carry the most robust data across the full spectrum of PsA domains, including peripheral joint disease, distal interphalangeal involvement, dactylitis, enthesitis, and axial disease, and have demonstrated inhibition of radiographic progression across these domains. For patients with prominent axial psoriatic arthritis in particular, IL-17 blockade remains the preferred mechanism, supported by an evidence base that IL-23 inhibitors have not yet matched for this specific manifestation. That said, guselkumab has recently demonstrated radiographic benefit in psoriatic arthritis, and the differentiation between IL-17 and IL-23 agents in this domain continues to evolve. Conversely, IL-17 inhibitors carry meaningful contraindications in patients with inflammatory bowel disease — a comorbidity that is not uncommon in patients with psoriasis — whereas IL-23 inhibitors can be used across a far broader comorbidity range.

In this segment of the video discussion on psoriasis treatment selection, Bruce Strober, MD, PhD, Clinical Professor of Dermatology at Yale University School of Medicine, describes the practical algorithm he applies at the point of prescribing. IL-23 inhibitors occupy a favored default position in his treatment approach for most patients with skin-predominant disease: they offer infrequent maintenance dosing, an essentially unrestricted comorbidity profile outside of active infection, and long-term durability data that compare favorably with other biologic classes. IL-17 inhibitors are reserved primarily for patients with significant psoriatic arthritis — particularly those with axial involvement — where the evidence for superior joint outcomes justifies accepting the more restrictive contraindication profile. Icotrokinra and other oral agents are positioned for patients who prioritize the oral route and can accept a somewhat lower efficacy ceiling than the most potent injectable biologics. This mechanism-first framework, calibrated by comorbidity and arthritis pattern before patient preference is layered on top, reflects the current complexity of psoriasis care and the degree to which therapeutic selection has evolved from a simple stepwise escalation into a nuanced, multidimensional clinical decision.